Who
Anthony Gregg Lapointe
Director
Company insider
Files Form 4 as: Director, Soligenix; Director, Rigel Pharmaceuticals; Director, Astria Therapeutics; Director, Sciclone Pharmaceuticals; Director, Cerenome; Director, Raptor Pharmaceutical; Director, ImmunoCellular Therapeutics; Director, Questcor Pharmaceuticals.
In numbers
- Trades disclosed
- 102
- Buys
- 1
- Sells
- 0
- Bought
- $205K
- Sold
- $0
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 1 Jan 2006
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —54 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —74 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —128 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —63 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —121 at $0.00 | filing |
| 12 Oct 2026filed 13 Oct 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code D | —192 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,947 at $0.00 | filing |
| 17 Sep 2026filed 18 Sep 2026 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,947 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,666 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —8,333 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,666 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —8,333 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,550 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,100 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Astria Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —26,550 | filing |
News
Reviewing Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS)SNGX · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name Anthony Gregg Lapointe; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.